Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Otto Metzger(Dana-Farber Cancer Institute), Daniel G. Stover(Harvard University), Michael Untch(Helios Kliniken), Mark A. Watson(Washington University in St. Louis), Peter Ansell(AbbVie (United States)), Carsten Denkert(Philipps University of Marburg), William M. Sikov(Providence College), Katharine A. Collier(The Ohio State University), Norman Wolmark(NSABP Foundation), David Maag(AbbVie (United States)), Lijun Cheng(The Ohio State University), Charles E. Geyer(Magee-Womens Hospital), Junu Bae(The Ohio State University), Jens Huober(University of St.Gallen), Joyce O’Shaughnessy(Baylor University Medical Center), Mathew Cherian(The Ohio State University Wexner Medical Center), Sibylle Loibl(Goethe University Frankfurt), Sarah Asad(The Ohio State University), Hope S. Rugo(City of Hope), Lang Li(Sun Yat-sen University), Gϋnter von Minckwitz(German Breast group), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Mehra Golshan(Yale New Haven Hospital), Priya Rastogi(UPMC Hillman Cancer Center)
Cited by 37
Related Papers
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
|New England Journal of Medicine|2005|5.3k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k